Every Form 4 that Roivant Sciences Ltd. (ROIV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ROIV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ROIV filings page.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold had 5,133 Common Shares withheld on September 10, 2026 to satisfy tax withholding obligations in connection with the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share tax withholding, he holds 8,960,761 Common Shares directly.
Roivant Sciences Ltd. (ROIV) director Oren Ilan reported a disposition of 2,378 Common Shares of the company on September 10, 2026. The shares were withheld by the issuer as a net settlement to cover applicable tax withholding obligations upon vesting of previously granted director equity awards. Following this tax-withholding transaction, Ilan directly holds 118,626 Common Shares of Roivant Sciences Ltd. No transactions were reported under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) reported that director Melissa B. Epperly had 2,179 Common Shares withheld on September 10, 2026, as a tax-withholding disposition connected to the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share settlement for tax liabilities, she directly holds 14,838 Common Shares.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald had 1,743 Common Shares withheld on September 10, 2026 as a net settlement to satisfy tax withholding obligations tied to vesting of previously granted director equity awards. The shares were valued at $40.94 per share, leaving her with 41,220 Common Shares held directly after this transaction. No Rule 10b5-1 trading plan is reported for this disposition.
Roivant Sciences Ltd. (ROIV) director James C. Momtazee reported a Form 4 transaction involving the withholding of 2,905 Common Shares on September 10, 2026. The shares were withheld at $40.94 per share to satisfy tax withholding obligations upon vesting of equity granted under the company’s Non-Employee Director Compensation Plan, leaving him with 106,905 Common Shares held directly.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported an option exercise and same-day sale of common shares. On September 8, 2026, she exercised options for 20,000 shares at $8.80 per share, then sold 20,000 common shares at a weighted average price between $39.90 and $40.00 per share under a Rule 10b5-1 trading plan. Following the exercise, she held 18,578 stock options that remain exercisable until April 19, 2033.
Roivant Sciences Ltd. (ROIV) reported that officer Eric Venker, President & Immunovant CEO, exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same date sold an aggregate of 200,000 Common Shares in multiple transactions at weighted average prices of $35.63 and $36.44 per share, under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following the option exercise, Venker reported 3,844,834 stock options remaining directly held.
Roivant Sciences Ltd. (ROIV) reported that its CFO, Richard Pulik, had 5,749 Common Shares withheld on 2026-08-20 to satisfy tax withholding obligations upon the vesting and settlement of previously granted RSUs. This "net settlement" left him with 271,810 Common Shares held directly, including shares purchased under the company’s Employee Stock Purchase Plan.
Roivant Sciences Ltd. (ROIV) reported an insider equity event involving Eric Venker, President & Immunovant CEO. On 2026-08-20, 13,909 common shares were withheld in a code F transaction at $36.84 per share as a net settlement of RSUs to cover tax withholding upon vesting. Following this withholding, Venker’s directly held stake is reported as 1,599,154 common shares. This reflects tax-related share settlement rather than an open-market sale.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold the resulting common shares over three days. He exercised options covering 335,174 Common Shares at an exercise price of $3.85 per share, fully vested per the award footnote, and received an equal number of Common Shares. On August 19, 20 and 21, 2026, he sold 172,899, 17,519 and 144,756 Common Shares, respectively, at weighted average prices of $37.17, $37.30 and $36.48 per share in multiple transactions within the stated price ranges.
Roivant Sciences Ltd. (ROIV) reported that President & CIO Mayukh Sukhatme exercised stock options and sold common shares over three days. On August 14, 17, and 18, 2026, options with a $3.85 exercise price were exercised to acquire an aggregate of 664,826 common shares, which were then sold in multiple open-market transactions at weighted average prices reported as approximately $36.23, $36.25, $36.59, and $37.18 per share, with actual trade prices ranging from $36.10 to $37.30, as described in the footnotes.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an option exercise and related share sale. On 2026-07-27 he exercised stock options for 200,000 Common Shares at $3.85 per share from a fully vested award, leaving 4,044,834 options of this grant outstanding, expiring April 19, 2032. He then sold 200,000 Common Shares at a weighted average price of $34.95 (with trades between $34.62 and $35.56), with the filing indicating use of a Rule 10b5-1 trading plan.
MOMTAZEE JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director James C. Momtazee received an award of 405 Common Shares on July 17, 2026 under the Non-Employee Director Compensation Plan at $0.00 per share. The award was fully vested on grant, bringing his directly held stake to 109,810 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 543 Common Shares on July 17, 2026 under the company’s Non-Employee Director Compensation Plan. The award was fully vested at grant and increased her directly held stake to 17,017 Common Shares.
Roivant Sciences Ltd. director Oren Ilan received an award of 775 Common Shares on July 17, 2026 at $0.0000 per share under the company’s Non-Employee Director Compensation Plan, fully vested as of the grant date.
After this grant, Ilan directly holds 121,004 Common Shares; the transaction is reported as a grant/award acquisition and was not made under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. director and CEO Matthew Gline reported a routine tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the company withheld 76,171 common shares, valued at $35.39 per share, to cover applicable tax obligations through a net settlement. Following this transaction, Gline directly holds 16,659,945 common shares, indicating he retains a substantial equity position in the company and that the reported disposition reflects tax withholding rather than an open-market sale.
Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares. She exercised stock options to acquire 10,000 common shares at $8.80 per share and on the same date sold 10,000 common shares at an average price of $34.90 per share.
Following these transactions, Fitzgerald directly holds 42,963 common shares of Roivant Sciences. The derivative entry shows 38,578 stock options remaining after the exercise, indicating she continues to have a meaningful option position as well as a direct equity stake.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 40,310 common shares withheld on June 30, 2026 to cover tax obligations. The shares were "net settled" from previously granted RSUs when they vested, rather than sold in the open market.
After this tax-withholding disposition, Torti directly holds 13,536,202 common shares, indicating this was a routine compensation-related event rather than a change in his overall investment stance.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme had 46,878 Common Shares withheld on June 30, 2026 at $35.39 per share. This was a tax-withholding disposition tied to the vesting of previously granted RSUs, not an open-market trade. After this net settlement, he directly holds 18,630,739 Common Shares.
Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026. She exercised options to acquire 17,750 Common Shares at an exercise price of $4.46 per share, increasing her direct common share holdings before subsequent sales.
That same day, she executed open-market sales totaling 17,750 Common Shares in two transactions: 2,748 shares at a weighted average price of $34.71 and 15,002 shares at a weighted average price of $34.32. The footnotes state these were filled across multiple trades within price ranges from $33.65 to $34.80. After the transactions, Epperly directly held 16,474 Common Shares and 169,166 stock options to purchase additional shares, with the option grant exercised here fully vested and expiring on July 19, 2032.
Roivant Sciences director Keith S. Manchester reported open-market sales totaling 1,638,163 Common Shares of Roivant Sciences Ltd. from June 26–30, 2026, at prices between $33.92 and $35.45 per share. The filing shows 200,000 shares sold from his direct holdings, leaving 1,748,403 shares held directly, and additional sales by QVT Financial Investment Cayman Ltd., which held 13,689,166 shares afterward. Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of those shares except for his pecuniary interest.
Roivant Sciences Ltd. reported insider-related share sales linked to an investment entity associated with director Daniel Allen Gold. QVT Financial Investment Cayman Ltd. completed open-market sales of a total of 1,438,163 common shares of Roivant Sciences over three days, at prices between $33.92 and $35.28 per share. After the most recent transaction, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares indirectly. Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership except to the extent of his pecuniary interest.
Roivant Sciences Ltd. disclosed that investment firm QVT Financial LP, through QVT Financial Investment Cayman Ltd., executed open-market sales of a total of 1,438,163 common shares over three days at prices around $33.92–$35.28 per share. Following these transactions, QVT Financial Investment Cayman Ltd. held 13,689,166 common shares, while footnotes state that QVT Financial LP may be deemed to beneficially own 23,723,074 Roivant common shares across related entities, although it disclaims beneficial ownership beyond any pecuniary interest.
Roivant Sciences Ltd. President & CIO Mayukh Sukhatme reported an exercise-and-sell pattern over two days. On June 25 and 26, he exercised options to acquire a total of 1,000,000 Common Shares at $3.85 per share and sold 1,000,000 Common Shares in open-market transactions.
The sales were executed at weighted average prices of $34.13 and $34.08 per share, each representing multiple trades within disclosed price ranges. Following these transactions, Sukhatme directly held 18,677,617 Common Shares. The underlying options exercised were fully vested and are no longer outstanding.
Roivant Sciences Ltd. reported insider transactions by President & Immunovant CEO Eric Venker involving both an option exercise and open-market sales of common shares.
Venker exercised stock options for 200,000 Common Shares at a conversion price of $3.85 per share and received fully vested shares. On the same date, he sold 46,234 Common Shares at a weighted average price of $33.51 and 153,766 Common Shares at a weighted average price of $33.05 in multiple open-market transactions within disclosed price ranges. Following these moves, he directly held 1,613,063 Common Shares and 4,244,834 stock options to purchase additional shares.
Roivant Sciences Ltd. CFO Richard Pulik reported a routine share disposition tied to equity compensation. On the RSU vesting date, 2,129 common shares at $31.43 per share were withheld by the company to satisfy tax withholding obligations through a net settlement of previously granted RSUs. Following this tax-related transfer, Pulik directly holds 276,420 common shares of Roivant Sciences Ltd.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a routine tax-related share disposition. On this Form 4, 3,582 common shares were surrendered at a value of $31.43 per share to cover tax withholding tied to the vesting of previously granted RSUs. After this net settlement, she directly holds 109,782 common shares, indicating the transaction reflects compensation and tax obligations rather than an open-market sale.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a set of transactions involving company shares. He exercised stock options to acquire 200,000 Common Shares at $3.85 per share, then sold 200,000 Common Shares in an open-market transaction at a weighted average price of $30.27 per share. Separately, 34,483 Common Shares were surrendered through a net settlement to cover tax withholding obligations on vested RSUs, which is not an open-market sale. After these transactions, Venker directly holds 1,613,063 Common Shares.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-withholding share disposition related to restricted stock units (RSUs). On this event, 18,962 common shares were withheld at a value of $32.41 per share to cover tax obligations triggered by the vesting and settlement of previously granted RSUs. After this non‑market transaction, Pulik directly holds 278,549 common shares, indicating he retains a substantial equity position in the company.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an exercise-and-sale transaction in the company’s common shares. He exercised stock options to acquire 200,000 common shares at $3.85 per share and sold 200,000 common shares in open-market transactions at a weighted average price of $29.59 per share, with individual trade prices ranging from $29.33 to $29.88. Following these transactions, he directly holds 1,647,546 common shares. A related stock option award to purchase common shares is described as fully vested.
Pulik Richard reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences CFO Richard Pulik received equity compensation on April 20, 2026. He was granted 60,644 Common Shares as restricted stock units and now holds 297,511 Common Shares directly. He also received 84,026 stock options to buy Common Shares at $29.08 per share, expiring in 2036.
The RSUs vest 25% one year after April 20, 2026, with the rest in twelve equal quarterly installments. The options vest 25% one year after that date, then in thirty-six equal monthly installments, all subject to his continued service.
Roivant Sciences Ltd. reported a compensation-related equity grant to Chief Accounting Officer Jennifer Humes. She received 29,173 Common Share RSUs, bringing her direct Common Share holdings to 113,364 shares after the award.
Humes was also granted 27,157 stock options to buy Common Shares at an exercise price of $29.08 per share, expiring on April 19, 2036. Both the RSUs and options have a vesting commencement date of April 20, 2026 and vest over time, subject to her continuous service with the company.
Roivant Sciences Ltd. director Oren Ilan reported compensation-related share movements. He received an award of 896 Common Shares under the company’s Non-Employee Director Compensation Plan, which was fully vested on the grant date. To cover tax withholding obligations on previously granted shares that vested and settled, 95 Common Shares were withheld and settled on a net basis by the company. Following these transactions, Ilan directly holds 120,229 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,405 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported an open-market sale of 13,538 Common Shares of Roivant Sciences on April 8, 2026. The weighted average sale price was $28.37 per share, with individual trades executed between $28.36 and $28.38. After this transaction, she directly holds 84,191 Common Shares.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026 to cover tax obligations tied to previously granted RSUs. The issuer net settled these RSUs to satisfy applicable tax withholding, and Torti now directly holds 13,576,512 common shares.
Roivant Sciences CEO Matthew Gline exercised capped value appreciation rights and had shares withheld to cover taxes. On March 30, 2026, 2,178,150 vested CVARs were settled into 97,319 Common Shares, and a portion of these was net-settled to satisfy tax withholding obligations. On March 31, 2026, additional Common Shares from previously granted RSUs were also net-settled for tax withholding. After these compensation-related transactions, Gline directly held 17,025,890 Common Shares, indicating he retained a large equity position and that the dispositions were primarily for tax obligations rather than open-market trading.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme exercised equity awards and had shares withheld for taxes. On March 30, 2026, he exercised 1,306,889 Capped Value Appreciation Rights, which were settled into 58,391 Common Shares based on the closing share price that day.
The issuer then conducted net share settlements to cover tax obligations, withholding 29,809 Common Shares at $26.41 related to the CVAR settlement and 187,512 Common Shares at $27.70 tied to previously granted RSUs. After these non‑market tax-withholding dispositions, Sukhatme directly owned 18,677,617 Common Shares.
Roivant Sciences director Meghan Fitzgerald exercised stock options for 70,000 Common Shares at an exercise price of $8.80 per share and immediately sold the same 70,000 shares in an open-market transaction. The sale had a weighted average price of $27.45 per share, with individual trades executed between $27.32 and $27.80. Following these transactions, Fitzgerald directly holds 42,963 Common Shares, and the exercised option award is now fully vested and exhausted.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-related share disposition tied to restricted stock units (RSUs). The company net-settled 1,546 Common Shares on March 20, 2026 to satisfy applicable tax withholding obligations upon RSU vesting, rather than through an open-market sale.
After this tax-withholding transaction, Pulik directly holds 236,867 Common Shares. This type of F-code transaction is a routine administrative step associated with equity-based compensation, reflecting shares withheld for taxes instead of cash payment.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the issuer net-settled 14,526 Common Shares at $27.70 per share to cover withholding obligations. After this non‑market transaction, Humes directly holds 97,729 Common Shares, indicating the event is compensation- and tax-driven rather than an open-market trade.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same day sold 200,000 Common Shares in open-market transactions at a weighted average price of $28.24 per share.
Following these transactions, Venker directly owned 1,647,546 Common Shares. The sale price reflects multiple trades within a range from $28.04 to $28.45, as disclosed in the filing footnotes.
Roivant Sciences Ltd. director Melissa B. Epperly reported an open-market sale of 41,861 common shares on March 16, 2026 at a weighted average price of $28.68 per share. The shares were sold in multiple trades priced between $28.50 and $28.84. After this transaction, she directly holds 15,804 common shares of Roivant Sciences.
Roivant Sciences Ltd. reported that CFO Richard Pulik had 1,000 common shares withheld at a price of $27.15 per share to cover tax obligations from the vesting of previously granted RSUs. After this tax-withholding disposition, he directly holds 238,413 common shares.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a Form 4 showing a tax-related share disposition. On this date, 7,051 common shares were withheld and net-settled by the company to satisfy tax withholding obligations arising from the vesting of previously granted RSUs. After this tax-withholding disposition, Venker directly owned 1,647,546 common shares.
Roivant Sciences Ltd. President and Vant Chair Frank Torti reported a series of stock option exercises and related share sales. Between February 19 and 23, he exercised options to acquire a total of 3,000,000 Common Shares at an exercise price of $3.85 per share and then sold the same number of shares in open-market transactions.
The sales covered 1,400,000, 1,012,610, and 587,390 Common Shares at weighted average prices of $27.42, $27.15, and $27.51 per share, respectively, with individual trades occurring between $26.70 and $27.80. After these transactions, Torti directly owned 13,736,547 Common Shares and held 3,026,184 stock options.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported exercising stock options and selling shares on the same day. He exercised options for 200,000 Common Shares at an exercise price of $3.85 per share, then sold 200,000 Common Shares in open-market transactions at a weighted average price of $26.49 per share, with individual sale prices ranging from $26.35 to $26.69. Following these transactions, he directly owned 1,654,597 Common Shares and held 5,044,834 stock options.
Roivant Sciences director-associated entity reports share sales. An investment entity, QVT Financial Investment Cayman Ltd., which is associated with director Keith S. Manchester, executed several indirect open-market sales of Roivant Sciences common shares between February 11 and 13, 2026.
Transactions included sales of 425,000 shares at $26.67, 150,000 shares at $26.72, 275,000 shares at $26.76, 150,784 shares at $26.49, and 225,000 shares at $26.50. Following these trades, QVT Financial Investment Cayman Ltd. is reported as indirectly holding 15,127,329 common shares.
The filing notes that Manchester is a shareholder of QVT Financial Investment Cayman Ltd. but has no voting or investment control over it and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.